Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Fatemeh Rafiee, Zahra Pourteymourfard-Tabrizi, Mohammad-Reza Mahmoudian-Sani, Ameneh Mehri-Ghahfarrokhi, Amin Soltani, Morteza Hashemzadeh-Chaleshtori & Mohammad-Saeid Jami. (2020) Differentiation of dental pulp stem cells into neuron-like cells. International Journal of Neuroscience 130:2, pages 107-116.
Read now
Read now
Hiide Yoshino. (2019) Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics 19:3, pages 185-193.
Read now
Read now
Carlayne Jackson, Mamede De Carvalho, Angela Genge, Terry Heiman-Patterson, Jeremy M. Shefner, Jenny Wei & Andrew A. Wolff. (2018) Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:7-8, pages 506-512.
Read now
Read now
Benoît Marin, Elisa Bianchi, Elisabetta Pupillo, Christian Lunetta, Lucio Tremolizzo, Giancarlo Logroscino, Adriano Chiò, Pierre Marie Preux & Ettore Beghi. (2016) Non-self-sufficiency as a primary outcome measure in ALS trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 17:1-2, pages 77-84.
Read now
Read now
Lorna Jane O'Doherty, Anne Hickey & Orla Hardiman. (2010) Measuring life quality, physical function and psychological well-being in neurological illness. Amyotrophic Lateral Sclerosis 11:5, pages 461-468.
Read now
Read now
Bert U. Kleine, Helenius J. Schelhaas, Gijs van Elswijk, Maarten C. de Rijk, Dick F. Stegeman & Machiel J. Zwarts. (2010) Prospective, blind study of the triple stimulation technique in the diagnosis of ALS. Amyotrophic Lateral Sclerosis 11:1-2, pages 67-75.
Read now
Read now
Carmen Castrillo-Viguera, Daniela L. Grasso, Elizabeth Simpson, Jeremy Shefner & Merit E. Cudkowicz. (2010) Clinical significance in the change of decline in ALSFRS-R. Amyotrophic Lateral Sclerosis 11:1-2, pages 178-180.
Read now
Read now
Paul Talman, Andrew Forbes & Susan Mathers. (2009) Clinical phenotypes and natural progression for motor neuron disease: Analysis from an Australian database. Amyotrophic Lateral Sclerosis 10:2, pages 79-84.
Read now
Read now
Ettore Beghi, Andrea Millul, Giancarlo Logroscino, Eugenio Vitelli, Anna Micheli, FOR THE SLALOM GROUP, Ettore Beghi, Andrea Millul, Giancarlo Logroscino, Eugenio Vitelli, Anna Micheli & FOR THE SLALOM GROUP. (2008) Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 9:3, pages 163-167.
Read now
Read now
Imelda J. M. De groot, Marcel W. M. Post, Tineke van Heuveln, Leonard H. Van den berg & Eline Lindeman. (2007) Cross‐sectional and longitudinal correlations between disease progression and different health‐related quality of life domains in persons with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 8:6, pages 356-361.
Read now
Read now
Imelda J. M. De Groot, Marcel W. M. Post, Tineke Van Heuveln, Leonard H. Van Den Berg & Eline Lindeman. (2006) Measurement of decline of functioning in persons with amyotrophic lateral sclerosis: Responsiveness and possible applications of the Functional Independence Measure, Barthel Index, Rehabilitation Activities Profile and Frenchay Activities Index. Amyotrophic Lateral Sclerosis 7:3, pages 167-172.
Read now
Read now
Gilbert Bensimon & Adam Doble. (2004) The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opinion on Drug Safety 3:6, pages 525-534.
Read now
Read now
Articles from other publishers (33)
Paolo Tornese, Stefania Lalli, Antoniangela Cocco & Alberto Albanese. (2022) Review of disease-modifying drug trials in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 93:5, pages 521-529.
Crossref
Crossref
Oriana Ciani, Maximilian Salcher-Konrad, Michela Meregaglia, Kathrine Smith, Sarah L. Gorst, Susanna Dodd, Paula R. Williamson & Giovanni Fattore. (2021) Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments. Journal of Clinical Epidemiology 136, pages 26-36.
Crossref
Crossref
Pavel Schischlevskij, Isabell Cordts, René Günther, Benjamin Stolte, Daniel Zeller, Carsten Schröter, Ute Weyen, Martin Regensburger, Joachim Wolf, Ilka Schneider, Andreas Hermann, Moritz Metelmann, Zacharias Kohl, Ralf A. Linker, Jan Christoph Koch, Claudia Stendel, Lars H. Müschen, Alma Osmanovic, Camilla Binz, Thomas Klopstock, Johannes Dorst, Albert C. Ludolph, Matthias Boentert, Tim Hagenacker, Marcus Deschauer, Paul Lingor, Susanne Petri & Olivia Schreiber-Katz. (2021) Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives. Brain Sciences 11:6, pages 748.
Crossref
Crossref
Tara Peseschkian, Isabell Cordts, René Günther, Benjamin Stolte, Daniel Zeller, Carsten Schröter, Ute Weyen, Martin Regensburger, Joachim Wolf, Ilka Schneider, Andreas Hermann, Moritz Metelmann, Zacharias Kohl, Ralf A. Linker, Jan Christoph Koch, Boriana Büchner, Ulrike Weiland, Erik Schönfelder, Felix Heinrich, Alma Osmanovic, Thomas Klopstock, Johannes Dorst, Albert C. Ludolph, Matthias Boentert, Tim Hagenacker, Marcus Deschauer, Paul Lingor, Susanne Petri & Olivia Schreiber-Katz. (2021) A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany. Brain Sciences 11:3, pages 372.
Crossref
Crossref
Panying Rong. (2020) Automated Acoustic Analysis of Oral Diadochokinesis to Assess Bulbar Motor Involvement in Amyotrophic Lateral Sclerosis. Journal of Speech, Language, and Hearing Research 63:1, pages 59-73.
Crossref
Crossref
Leila Bond, Gloria Bowen, Benjamin Mertens, Keelie Denson, Kathleen Jordan, Branislav Vidakovic & Cassie S. Mitchell. (2020) Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration. Behavioral Sciences 10:1, pages 33.
Crossref
Crossref
Ebru Altuntaş, Kübra Gözütok & Burcu Özkan. 2020. Neural Regenerative Nanomedicine. Neural Regenerative Nanomedicine
159
211
.
Alan Moore, Carolyn A. Young & Dyfrig A. Hughes. (2019) Health Utilities and Costs for Motor Neurone Disease. Value in Health 22:11, pages 1257-1265.
Crossref
Crossref
Agnese Gugliandolo, Placido Bramanti & Emanuela Mazzon. (2019) Mesenchymal Stem Cells: A Potential Therapeutic Approach for Amyotrophic Lateral Sclerosis?. Stem Cells International 2019, pages 1-16.
Crossref
Crossref
Annerieke C. van Groenestijn, Carin D. Schröder, Ruben P. A. van Eijk, Jan H. Veldink, Esther T. Kruitwagen-van Reenen, Jan T. Groothuis, Hepke F. Grupstra, Marga Tepper, Reinout O. van Vliet, Johanna M. A. Visser-Meily & Leonard H. van den Berg. (2019) Aerobic Exercise Therapy in Ambulatory Patients With ALS: A Randomized Controlled Trial. Neurorehabilitation and Neural Repair 33:2, pages 153-164.
Crossref
Crossref
Alan Moore, Carolyn A. Young & Dyfrig A. Hughes. (2018) Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease. Value in Health 21:11, pages 1322-1329.
Crossref
Crossref
R. Tortelli, M. Copetti, F. Panza, A. Fontana, R. Cortese, R. Capozzo, A. Introna, E. D'Errico, S. Zoccolella, S. Arcuti, D. Seripa, I. L. Simone & G. Logroscino. (2016) Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study. European Journal of Neurology 23:6, pages 1117-1125.
Crossref
Crossref
A. E. Elia, S. Lalli, M. R. Monsurrò, A. Sagnelli, A. C. Taiello, B. Reggiori, V. La Bella, G. Tedeschi & A. Albanese. (2015) Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. European Journal of Neurology 23:1, pages 45-52.
Crossref
Crossref
Hyun Young Kim, Heejaung Kim, Ki-Wook Oh, Seong-Il Oh, Seong-Ho Koh, Wonki Baik, Min Young Noh, Kyung Suk Kim & Seung Hyun Kim. (2014) Biological Markers of Mesenchymal Stromal Cells as Predictors of Response to Autologous Stem Cell Transplantation in Patients With Amyotrophic Lateral Sclerosis: An Investigator-Initiated Trial and In Vivo Study. Stem Cells 32:10, pages 2724-2731.
Crossref
Crossref
Risheng Xu, Anthony V. Serritella, Tanusree Sen, Justin M. Farook, Thomas W. Sedlak, Jay Baraban, Solomon H. Snyder & Nilkantha Sen. (2013) Behavioral Effects of Cocaine Mediated by Nitric Oxide-GAPDH Transcriptional Signaling. Neuron 78:4, pages 623-630.
Crossref
Crossref
Jonathan D. Glass, Nicholas M. Boulis, Karl Johe, Seward B. Rutkove, Thais Federici, Meraida Polak, Crystal Kelly & Eva L. Feldman. (2012) Lumbar Intraspinal Injection of Neural Stem Cells in Patients with Amyotrophic Lateral Sclerosis: Results of a Phase I Trial in 12 Patients. STEM CELLS 30:6, pages 1144-1151.
Crossref
Crossref
Dan H Moore, Jonathan S Katz & Robert G Miller. (2011) A review of clinical trial designs in amyotrophic lateral sclerosis. Neurodegenerative Disease Management 1:6, pages 481-490.
Crossref
Crossref
Annerieke C van Groenestijn, Ingrid GL van de Port, Carin D Schröder, Marcel WM Post, Hepke F Grupstra, Esther T Kruitwagen, Harmen van der Linde, Reinout O van Vliet, Margreet GH van de Weerd, Leonard H van den Berg & Eline Lindeman. (2011) Effects of aerobic exercise therapy and cognitive behavioural therapy on functioning and quality of life in amyotrophic lateral sclerosis: protocol of the FACTS-2-ALS trial. BMC Neurology 11:1.
Crossref
Crossref
Peter D. DonofrioRichard Bedlack. (2011) Historical controls in ALS trials. Neurology 77:10, pages 936-937.
Crossref
Crossref
J. Simon Lunn, Stacey A. Sakowski, Junguk Hur & Eva L. Feldman. (2011) Stem cell technology for neurodegenerative diseases. Annals of Neurology 70:3, pages 353-361.
Crossref
Crossref
Hideyuki Takeuchi, Hiroyuki Mizoguchi, Yukiko Doi, Shijie Jin, Mariko Noda, Jianfeng Liang, Hua Li, Yan Zhou, Rarami Mori, Satoko Yasuoka, Endong Li, Bijay Parajuli, Jun Kawanokuchi, Yoshifumi Sonobe, Jun Sato, Koji Yamanaka, Gen Sobue, Tetsuya Mizuno & Akio Suzumura. (2011) Blockade of Gap Junction Hemichannel Suppresses Disease Progression in Mouse Models of Amyotrophic Lateral Sclerosis and Alzheimer's Disease. PLoS ONE 6:6, pages e21108.
Crossref
Crossref
Petra Steinacker, Andreas Hawlik, Stefan Lehnert, Olaf Jahn, Stephen Meier, Evamaria Görz, Kerstin E. Braunstein, Marija Krzovska, Birgit Schwalenstöcker, Sarah Jesse, Christian Pröpper, Tobias Böckers, Albert Ludolph & Markus Otto. (2010) Neuroprotective Function of Cellular Prion Protein in a Mouse Model of Amyotrophic Lateral Sclerosis. The American Journal of Pathology 176:3, pages 1409-1420.
Crossref
Crossref
Keyte Guedes, Cecília Pereira, Karina Pavan & Berenice Cataldo Oliveira Valério. (2010) Cross-cultural adaptation and validation of als Functional Rating Scale-Revised in Portuguese language. Arquivos de Neuro-Psiquiatria 68:1, pages 44-47.
Crossref
Crossref
Petra Steinacker, Corinna Hendrich, Anne-Dorte Sperfeld, Sarah Jesse, Stefan Lehnert, Alice Pabst, Christine A. F. von Arnim, Felix M. Mottaghy, Ingo Uttner, Hayrettin Tumani, Albert Ludolph & Markus Otto. (2009) Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Journal of Neural Transmission 116:9, pages 1169-1178.
Crossref
Crossref
Zachary Simmons. (2009) Can we eliminate placebo in ALS clinical Trials?. Muscle & Nerve 39:6, pages 861-865.
Crossref
Crossref
Andrea Kübler. 2009. The Neurology of Consciousness. The Neurology of Consciousness
217
233
.
Adam Czaplinski, Albert A. Yen, Ericka P. Simpson & Stanley H. Appel. (2006) Predictability of disease progression in amyotrophic lateral sclerosis. Muscle & Nerve 34:6, pages 702-708.
Crossref
Crossref
S. G. Mueller, N. Schuff & M. W. Weiner. (2006) Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS. NMR in Biomedicine 19:6, pages 655-668.
Crossref
Crossref
V. Danel-Brunaud. (2006) Évaluation du handicap et de la qualité de vie dans la sclérose latérale amyotrophique. Revue Neurologique 162, pages 200-204.
Crossref
Crossref
Niranjanan Nirmalananthan & Linda Greensmith. (2005) Amyotrophic lateral sclerosis: recent advances and future therapies. Current Opinion in Neurology 18:6, pages 712-719.
Crossref
Crossref
Matthew C Kiernan. (2005) Riluzole: a glimmer of hope in the treatment of motor neurone disease. Medical Journal of Australia 182:7, pages 319-320.
Crossref
Crossref
Jennica MC Winhammar, Dominic B Rowe, Robert D Henderson & Matthew C Kiernan. (2005) Assessment of disease progression in motor neuron disease. The Lancet Neurology 4:4, pages 229-238.
Crossref
Crossref
Andrea Kübler & Nicola Neumann. 2005. The Boundaries of Consciousness: Neurobiology and Neuropathology. The Boundaries of Consciousness: Neurobiology and Neuropathology
513
525
.